Table 2.

Univariate and multivariate analysis of risk factors for progression: cohort A.

Factors	n	HR	Univariate	pvalue	Multivariate	P multi
			IC95% (HR)		HR IC95% (HR)
Age at metastatic diagnosis	233	1	[0.99; 1.02]	0.723	1.00 [0.99; 1.01]	0.942
Hormone receptor status
1 - Négative	98	1		0.709	1	0.800
2 - Positive	133	1.03	[0.76; 1.40]		1.08 [0.76; 1.48]
3 - unknown	2	1.92	[0.47; 7.86]		1.48 [0.36; 6.18]
Liver metastasis
0 - no	119	1		0.371	1	0.093
1 - yes	114	1.15	[0.85; 1.55]		1.32 [0.95; 1.83]
First line duration
<12 mois	129	1		0.003	1	0.017
≥12 mois	104	0.63	[0.46; 0.86]		0.66 [0.49; 0.91]
HER2 status
HER2 3+	212	1		0.004	1	0.001
HER2 2+ (FISH amplified)	20	2.29	[1.38; 3.88]		2.28 [1.36; 3.84]
De novo/recurrent
De novo	106	1		0.285	1	0.1027
Recurrent	125	1.18	[0.87; 1.60]		1.44 [0.94; 2.22]
Trastuzumab in neo/adjuvant setting
No	152	1		0.745	1	0.582
Yes	81	1.05	[0.77; 1.45]		0.88 [0.57; 1.37]